SCOTTSDALE, Ariz., Nov. 14 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for MS therapies.
In this report, entitled "MedPredict Thought Leader Insight & Analysis: Multiple Sclerosis," physician experts discuss the key controversies emerging from ECTRIMS (European Committee for Treatment and Research in MS) 2007, including:
-- Early aggressive therapy vs. more conservative approaches.
-- The negative results from REGARD, and implications for the powering of
MS trials. The report offers predictions on results expected in the
BEYOND, PreCISe and OLYMPUS.
-- The potential for pulmonary delivery of interferon and Copaxone.
-- The numerous orally available drugs in development for MS. The report
reviews the benefits and drawbacks of fingolimod, other S1Ps,
short-acting VLA4, teriflunomide, laquinimod, fampridine, fumarates and
other oral options, and predicts where they will fall on the
-- The status and potential of a number of vaccine approaches.
-- Intriguing neuroprotection / neuroregeneration strategies, including
LINGO, anti-myelin-associated-glycoprotein MAb and remyelination MAb.
Drugs/Mechanisms mentioned in this report include: S1P agonists
(fingolimod; Novartis, S1P1; Roche/Actelion, Sphingomab; Lpath, S1P1
modulators; Epix / Amgen), inhibitors of DNA synthesis/repair
(teriflunomide; Sanofi-Aventis, cladribine; Ivax/Serono), potassium channel
blockers (fampridine; Acorda, BNC-245; Bionomics), interferons (Avonex;
Biogen, Rebif; Ares-Serono, Betaseron; Bayer-Schering and Biferonex;
Biopartners Holdings), VLA4 inhibitors (Tysabri; Biogen/Elan, firategrast;
GlaxoSmithKline, CDP-323; UCB/Biogen; ATL1102 (Antisense Th
|SOURCE MedPredict Market Research|
Copyright©2007 PR Newswire.
All rights reserved